Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2003 9
2004 9
2005 9
2006 7
2007 5
2008 7
2009 3
2010 6
2011 2
2012 8
2013 7
2014 6
2015 7
2016 5
2017 4
2018 5
2019 4
2020 3
2021 8
2022 5
2023 8
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

116 results

Results by year

Filters applied: . Clear all
Page 1
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK; ToGA Trial Investigators. Bang YJ, et al. Among authors: ruschoff j. Lancet. 2010 Aug 28;376(9742):687-97. doi: 10.1016/S0140-6736(10)61121-X. Epub 2010 Aug 19. Lancet. 2010. PMID: 20728210 Clinical Trial.
ISH-based HER2 diagnostics.
Rüschoff J, Nagelmeier I, Jasani B, Stoss O. Rüschoff J, et al. Pathologe. 2021 Nov;42(Suppl 1):62-68. doi: 10.1007/s00292-020-00878-6. Epub 2020 Dec 21. Pathologe. 2021. PMID: 33346874 Review. English.
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.
Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Láng I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Rüschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD; Herceptin Adjuvant (HERA) Trial Study Team. Piccart-Gebhart MJ, et al. Among authors: ruschoff j. N Engl J Med. 2005 Oct 20;353(16):1659-72. doi: 10.1056/NEJMoa052306. N Engl J Med. 2005. PMID: 16236737 Free article. Clinical Trial.
Erratum zu: Testung auf Mismatch-Reparatur-Defizienz und Mikrosatelliteninstabilität.
Rüschoff J, Schildhaus HU, Rüschoff JH, Jöhrens K, Bocker-Edmonston T, Dietmaier W, Bläker H, Baretton G, Horst D, Dietel M, Hartmann A, Klauschen F, Merkelbach-Bruse S, Stenzinger A, Schöniger S, Tiemann M, Weichert W, Büttner R. Rüschoff J, et al. Pathologie (Heidelb). 2023 Nov;44(Suppl 2):71-72. doi: 10.1007/s00292-023-01226-0. Pathologie (Heidelb). 2023. PMID: 37656216 Free PMC article. German. No abstract available.
[ISH-based HER2 diagnostics].
Rüschoff J, Nagelmeier I, Jasani B, Stoss O. Rüschoff J, et al. Pathologe. 2020 Nov;41(6):606-613. doi: 10.1007/s00292-020-00841-5. Pathologe. 2020. PMID: 33001242 Review. German.
HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer.
Van Cutsem E, Bang YJ, Feng-Yi F, Xu JM, Lee KW, Jiao SC, Chong JL, López-Sanchez RI, Price T, Gladkov O, Stoss O, Hill J, Ng V, Lehle M, Thomas M, Kiermaier A, Rüschoff J. Van Cutsem E, et al. Among authors: ruschoff j. Gastric Cancer. 2015 Jul;18(3):476-84. doi: 10.1007/s10120-014-0402-y. Epub 2014 Jul 20. Gastric Cancer. 2015. PMID: 25038874 Free PMC article. Clinical Trial.
Comparison of HercepTest™ mAb pharmDx (Dako Omnis, GE001) with Ventana PATHWAY anti-HER-2/neu (4B5) in breast cancer: correlation with HER2 amplification and HER2 low status.
Rüschoff J, Friedrich M, Nagelmeier I, Kirchner M, Andresen LM, Salomon K, Portier B, Sredni ST, Schildhaus HU, Jasani B, Grzelinski M, Viale G. Rüschoff J, et al. Virchows Arch. 2022 Nov;481(5):685-694. doi: 10.1007/s00428-022-03378-5. Epub 2022 Aug 16. Virchows Arch. 2022. PMID: 35970977 Free PMC article.
Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability.
Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, Rüschoff J, Fishel R, Lindor NM, Burgart LJ, Hamelin R, Hamilton SR, Hiatt RA, Jass J, Lindblom A, Lynch HT, Peltomaki P, Ramsey SD, Rodriguez-Bigas MA, Vasen HF, Hawk ET, Barrett JC, Freedman AN, Srivastava S. Umar A, et al. Among authors: ruschoff j. J Natl Cancer Inst. 2004 Feb 18;96(4):261-8. doi: 10.1093/jnci/djh034. J Natl Cancer Inst. 2004. PMID: 14970275 Free PMC article.
Testing for deficient mismatch repair and microsatellite instability : A focused update.
Rüschoff J, Schildhaus HU, Rüschoff JH, Jöhrens K, Bocker Edmonston T, Dietmaier W, Bläker H, Baretton G, Horst D, Dietel M, Hartmann A, Klauschen F, Merkelbach-Bruse S, Stenzinger A, Schöniger S, Tiemann M, Weichert W, Büttner R. Rüschoff J, et al. Pathologie (Heidelb). 2023 Nov;44(Suppl 2):61-70. doi: 10.1007/s00292-023-01208-2. Epub 2023 Oct 24. Pathologie (Heidelb). 2023. PMID: 37874379 Free PMC article. Review.
Spectrum and frequencies of mutations in MSH2 and MLH1 identified in 1,721 German families suspected of hereditary nonpolyposis colorectal cancer.
Mangold E, Pagenstecher C, Friedl W, Mathiak M, Buettner R, Engel C, Loeffler M, Holinski-Feder E, Müller-Koch Y, Keller G, Schackert HK, Krüger S, Goecke T, Moeslein G, Kloor M, Gebert J, Kunstmann E, Schulmann K, Rüschoff J, Propping P. Mangold E, et al. Among authors: ruschoff j. Int J Cancer. 2005 Sep 20;116(5):692-702. doi: 10.1002/ijc.20863. Int J Cancer. 2005. PMID: 15849733 Free article.
116 results